At a glance
- Originator Kyowa Hakko
- Class Indoles; Mesylates; Osteoporosis therapies
- Mechanism of Action Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Postmenopausal osteoporosis
Most Recent Events
- 26 Oct 2006 Discontinued - Preclinical for Postmenopausal osteoporosis in Japan (PO)
- 12 Mar 2003 No development reported - Preclinical for Postmenopausal osteoporosis in Japan (PO)
- 26 May 2001 Profile reviewed but no significant changes made